4.4 Review

LZTR1: A promising adaptor of the CUL3 family

Journal

ONCOLOGY LETTERS
Volume 22, Issue 1, Pages -

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2021.12825

Keywords

Noonan syndrome; glioblastoma; LZTR1; CUL3; ubiquitin ligase; ubiquitination; RAS; MAPK signaling pathway

Categories

Funding

  1. Natural Science Foundation of Zhejiang Province [LY20C070001]
  2. National Natural Science Foundation of China [31801165]
  3. Natural Science Foundation of Ningbo [2018A610213]
  4. National Undergraduate Training Program for Innovation and Entrepreneurship [202011646030]
  5. Program of Xinmiao (Potential) Talents in Zhejiang Province [2019R405061, 2019R405011, 2020R405039]
  6. Student Research and Innovation Program of Ningbo University [2020SRIP1923, 2020SRIP1919, 2020SRIP1902, 2020SRIP1901]
  7. K. C. Wong Magna Fund in Ningbo University

Ask authors/readers for more resources

The study focuses on the role of LZTR1 in cancer and neurological diseases, emphasizing its importance in the pathogenesis of these conditions. Understanding the normal function and mutations of LZTR1 is crucial for targeted therapy.
The study of the disorders of ubiquitin-mediated proteasomal degradation may unravel the molecular basis of human diseases, such as cancer (prostate cancer, lung cancer and liver cancer, etc.) and nervous system disease (Parkinson's disease, Alzheimer's disease and Huntington's disease, etc.) and help in the design of new therapeutic methods. Leucine zipper-like transcription regulator 1 (LZTR1) is an important substrate recognition subunit of cullin-RING E3 ligase that plays an important role in the regulation of cellular functions. Mutations in LZTR1 and dysregulation of associated downstream signaling pathways contribute to the pathogenesis of Noonan syndrome (NS), glioblastoma and chronic myeloid leukemia. Understanding the molecular mechanism of the normal function of LZTR1 is thus critical for its eventual therapeutic targeting. In the present review, the structure and function of LZTR1 are described. Moreover, recent advances in the current knowledge of the functions of LZTR1 in NS, glioblastoma (GBM), chronic myeloid leukemia (CML) and schwannomatosis and the influence of LZTR1 mutations are also discussed, providing insight into how LZTR1 may be targeted for therapeutic purposes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available